Analysis summary
Data coverage: Price-data record updated 14 September 2026, 12:44 pm +05:30. Annual results through Mar 2025; quarterly results through Sep 2025; cash flow through Mar 2026. Each section can have a different reporting period. The share price is not live.
Valuation in context
Bafna Pharmaceuticals Ltd: the stored intrinsic value estimate is ₹140.98, compared with a stored share price of ₹301.00. The model value is 53.2% below that quote. The model classifies this as overvalued; it is an estimate dependent on the inputs and assumptions, not a price target or a buy/sell recommendation.
Operating performance
Revenue for Mar 2025 was ₹146.00 Cr, versus ₹152.00 Cr in Mar 2024 (-3.9% year on year). Net profit for Mar 2025 was ₹4.00 Cr, versus ₹7.00 Cr in Mar 2024 (-42.9% year on year). These are the latest annual periods stored on this page; check the quarterly table separately for more recent developments.
Cash generation
For the same Mar 2025 period, operating cash flow was ₹22.00 Cr against net profit of ₹4.00 Cr. Cash flow covered 5.50 times reported profit. Cash generation supports the reported profit for this period; check whether this continues over several years.
Balance-sheet check
Reported borrowings were ₹37.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.
How to use the valuation and peer comparisons
The Intrinsic Value panel combines the available model estimates using the displayed weights. Earnings, cash-flow, dividend and asset-based methods can give very different answers. The displayed 12% cost of equity and 4% terminal growth assumptions apply where relevant; historical EPS growth is not a promise of future growth. Use the individual values and their spread to judge sensitivity.
The peer group follows the stored industry classification and may include different business models. Compare reporting periods, leverage and recurring earnings before interpreting a valuation gap. For banks and other financial businesses, capital adequacy and asset quality can be more informative than industrial-company cash-flow ratios.
Sources: Company data source. Check the company filings linked by the source for the reporting basis and exceptional items.
Automatically generated interpretation of the stored financial data, not a separately researched analyst opinion. Missing data is not evidence of poor performance. New filings become available here after the existing data refresh process captures them.
Investment Snapshot
Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores use stored reporting periods and are screening indicators, not investment recommendations. Missing health ratios are excluded. Broad industry groups and financial-sector accounting can limit comparability.
Share Price and Basic Stock Data
Last Updated: September 14, 2026, 12:44 pm
| PEG Ratio | 7.01 |
|---|
Understand these figures: how to read the P/E ratio, ROE versus earnings per share, and calculate intrinsic value.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Bafna Pharmaceuticals Ltd | 713 Cr. | 301 | 318/94.8 | 91.5 | 40.6 | 0.00 % | 11.9 % | 12.3 % | 10.0 |
| Wanbury Ltd | 837 Cr. | 239 | 360/162 | 19.5 | 18.1 | 0.00 % | 36.6 % | 76.5 % | 10.0 |
| Kilitch Drugs (India) Ltd | 583 Cr. | 167 | 220/117 | 19.4 | 80.0 | 0.00 % | 13.4 % | 10.6 % | 10.0 |
| Kopran Ltd | 936 Cr. | 194 | 219/107 | 37.5 | 110 | 1.55 % | 6.65 % | 4.91 % | 10.0 |
| Albert David Ltd | 482 Cr. | 844 | 932/580 | 21.4 | 686 | 0.59 % | 0.82 % | 0.44 % | 10.0 |
| Industry Average | 22,605.02 Cr | 1,259.48 | 55.53 | 211.24 | 0.38% | 26.17% | 16.63% | 6.06 |
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 21.96 | 34.22 | 42.24 | 41.95 | 40.68 | 28.44 | 41.40 | 33.29 | 40.32 | 33.19 | 39.06 | 34.62 | 35.47 |
| Expenses | 19.42 | 31.18 | 34.62 | 35.66 | 36.67 | 30.51 | 38.51 | 32.08 | 36.53 | 30.13 | 35.95 | 29.55 | 31.19 |
| Operating Profit | 2.54 | 3.04 | 7.62 | 6.29 | 4.01 | -2.07 | 2.89 | 1.21 | 3.79 | 3.06 | 3.11 | 5.07 | 4.28 |
| OPM % | 11.57% | 8.88% | 18.04% | 14.99% | 9.86% | -7.28% | 6.98% | 3.63% | 9.40% | 9.22% | 7.96% | 14.64% | 12.07% |
| Other Income | 0.64 | 1.93 | 0.26 | 1.87 | 0.16 | 0.98 | 0.52 | 0.16 | 1.02 | 0.18 | -0.76 | 0.60 | 1.18 |
| Interest | 0.45 | 0.58 | 0.70 | 0.60 | 0.44 | 0.58 | 0.68 | 0.65 | 0.62 | 0.64 | 0.82 | 0.91 | 0.86 |
| Depreciation | 1.12 | 1.40 | 1.53 | 1.21 | 1.24 | 1.27 | 1.27 | 1.44 | 1.58 | 1.66 | 0.22 | 1.37 | 1.47 |
| Profit before tax | 1.61 | 2.99 | 5.65 | 6.35 | 2.49 | -2.94 | 1.46 | -0.72 | 2.61 | 0.94 | 1.31 | 3.39 | 3.13 |
| Tax % | 0.00% | 0.00% | 4.96% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit | 1.61 | 3.00 | 5.37 | 6.35 | 2.48 | -2.94 | 1.46 | -0.72 | 2.62 | 0.95 | 1.31 | 3.39 | 3.12 |
| EPS in Rs | 0.68 | 1.27 | 2.27 | 2.68 | 1.05 | -1.24 | 0.62 | -0.30 | 1.11 | 0.40 | 0.55 | 1.43 | 1.32 |
Last Updated: January 2, 2026, 8:31 am
Profit & Loss - Annual Report
Last Updated: February 23, 2026, 12:35 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 177 | 100 | 85 | 65 | 46 | 44 | 42 | 71 | 85 | 115 | 152 | 146 | 147 |
| Expenses | 156 | 116 | 82 | 70 | 81 | 57 | 41 | 61 | 73 | 100 | 141 | 135 | 132 |
| Operating Profit | 21 | -16 | 3 | -5 | -35 | -13 | 1 | 10 | 12 | 16 | 11 | 11 | 16 |
| OPM % | 12% | -16% | 3% | -8% | -77% | -30% | 3% | 14% | 14% | 14% | 7% | 8% | 11% |
| Other Income | 1 | 40 | 1 | 1 | 31 | 0 | -23 | 1 | -0 | 3 | 4 | 1 | 2 |
| Interest | 12 | 12 | 12 | 11 | 7 | 2 | 0 | 1 | 1 | 2 | 2 | 3 | 3 |
| Depreciation | 8 | 5 | 4 | 4 | 4 | 3 | 3 | 4 | 5 | 5 | 5 | 5 | 5 |
| Profit before tax | 2 | 6 | -13 | -19 | -14 | -18 | -25 | 6 | 5 | 12 | 7 | 4 | 10 |
| Tax % | 40% | -0% | -3% | -4% | 15% | 8% | 0% | 0% | 0% | 2% | 0% | 0% | |
| Net Profit | 1 | 6 | -12 | -18 | -16 | -20 | -25 | 6 | 5 | 11 | 7 | 4 | 10 |
| EPS in Rs | 0.72 | 3.28 | -6.53 | -9.90 | -6.95 | -8.34 | -106.53 | 2.46 | 2.21 | 4.79 | 3.11 | 1.75 | 4.08 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Growth
Last Updated: September 5, 2025, 12:15 am
Balance Sheet
Last Updated: June 17, 2026, 6:00 am
| Month | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 19 | 19 | 19 | 24 | 24 | 2 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 53 | 41 | 26 | 17 | -3 | 49 | 33 | 38 | 50 | 57 | 61 | 72 |
| Borrowings | 64 | 80 | 82 | 47 | 46 | 3 | 15 | 11 | 23 | 24 | 28 | 37 |
| Other Liabilities | 50 | 45 | 40 | 40 | 54 | 17 | 14 | 17 | 33 | 42 | 40 | 42 |
| Total Liabilities | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 153 | 176 |
| Fixed Assets | 49 | 47 | 43 | 40 | 37 | 35 | 36 | 39 | 40 | 40 | 59 | 82 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 2 | 12 | 7 | 3 |
| Investments | 18 | 18 | 18 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 118 | 120 | 106 | 86 | 82 | 36 | 50 | 51 | 88 | 95 | 87 | 91 |
| Total Assets | 185 | 185 | 167 | 128 | 121 | 71 | 86 | 90 | 130 | 148 | 153 | 176 |
Cash Flow
| Month | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 2.00 | -5.00 | 20.00 | 40.00 | -1.00 | -36.00 | -20.00 | 2.00 | -2.00 | -6.00 | 0.00 | -10.00 |
This table and the chart use the Free Cash Flow row from the same stored cash-flow statement. Free cash flow generally measures operating cash flow after capital expenditure; check the source definition and reporting basis. It is not operating profit minus borrowings.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 192 | 303 | 291 | 302 | 195 | 208 | 52 | 49 | 63 | 130 | 109 | 101 |
| Inventory Days | 78 | 66 | 92 | 118 | 102 | 122 | 208 | 154 | 185 | 129 | 125 | 127 |
| Days Payable | 116 | 149 | 169 | 164 | 265 | 517 | 229 | 107 | 113 | 165 | 149 | 140 |
| Cash Conversion Cycle | 155 | 220 | 214 | 255 | 31 | -188 | 31 | 96 | 135 | 94 | 84 | 88 |
| Working Capital Days | 41 | 56 | 125 | -36 | -108 | -210 | 89 | 121 | 123 | 104 | 92 | 74 |
| ROCE % | 9% | -13% | -0% | -6% | -35% | -21% | -3% | 10% | 11% | 16% | 9% | 8% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -15.52 | -11.48 | -7.15 | -10.43 | -8.80 |
| Diluted EPS (Rs.) | -15.52 | -11.48 | -7.15 | -10.43 | -8.80 |
| Cash EPS (Rs.) | -89.52 | -6.29 | -5.47 | -8.17 | -5.51 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -17.59 | 7.97 | 15.73 | 22.57 | 30.95 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -17.59 | 7.97 | 15.73 | 22.57 | 30.95 |
| Revenue From Operations / Share (Rs.) | 179.54 | 18.33 | 19.94 | 34.82 | 45.73 |
| PBDIT / Share (Rs.) | 6.25 | -5.36 | -1.61 | -2.50 | 1.34 |
| PBIT / Share (Rs.) | -7.56 | -6.83 | -3.29 | -4.76 | -1.27 |
| PBT / Share (Rs.) | -103.32 | -7.30 | -6.22 | -10.91 | -8.21 |
| Net Profit / Share (Rs.) | -103.32 | -7.76 | -7.15 | -10.43 | -8.12 |
| NP After MI And SOA / Share (Rs.) | -104.54 | -7.98 | -7.07 | -10.23 | -7.52 |
| PBDIT Margin (%) | 3.48 | -29.26 | -8.05 | -7.18 | 2.92 |
| PBIT Margin (%) | -4.20 | -37.28 | -16.47 | -13.68 | -2.76 |
| PBT Margin (%) | -57.54 | -39.86 | -31.19 | -31.34 | -17.95 |
| Net Profit Margin (%) | -57.54 | -42.32 | -35.84 | -29.95 | -17.74 |
| NP After MI And SOA Margin (%) | -58.22 | -43.52 | -35.48 | -29.38 | -16.44 |
| Return on Networth / Equity (%) | 0.00 | -99.01 | -44.12 | -44.73 | -24.28 |
| Return on Capital Employeed (%) | -3.29 | -33.22 | -9.90 | -9.17 | -2.41 |
| Return On Assets (%) | -34.67 | -15.79 | -12.09 | -10.70 | -7.27 |
| Long Term Debt / Equity (X) | -0.71 | 1.21 | 0.61 | 0.91 | 0.60 |
| Total Debt / Equity (X) | -0.71 | 2.43 | 1.23 | 1.93 | 1.39 |
| Asset Turnover Ratio (%) | 0.44 | 0.33 | 0.30 | 0.36 | 0.44 |
| Current Ratio (X) | 2.11 | 0.68 | 0.81 | 0.94 | 1.29 |
| Quick Ratio (X) | 1.44 | 0.55 | 0.63 | 0.74 | 1.11 |
| Inventory Turnover Ratio (X) | 2.24 | 2.66 | 1.55 | 0.89 | 0.97 |
| Interest Coverage Ratio (X) | 15.48 | -5.97 | -0.54 | -0.40 | 0.19 |
| Interest Coverage Ratio (Post Tax) (X) | -18.72 | -8.10 | -1.44 | -0.69 | -0.16 |
| Enterprise Value (Cr.) | -3.29 | 69.21 | 109.10 | 134.30 | 133.55 |
| EV / Net Operating Revenue (X) | -0.07 | 1.60 | 2.31 | 2.07 | 1.57 |
| EV / EBITDA (X) | -2.22 | -5.45 | -28.71 | -28.76 | 53.52 |
| MarketCap / Net Operating Revenue (X) | 0.04 | 0.59 | 1.40 | 0.84 | 0.65 |
| Price / BV (X) | -0.49 | 1.36 | 1.75 | 1.29 | 0.96 |
| Price / Net Operating Revenue (X) | 0.04 | 0.59 | 1.40 | 0.84 | 0.65 |
| EarningsYield | -11.80 | -0.72 | -0.25 | -0.34 | -0.25 |
Frequently asked questions
What is the intrinsic value of Bafna Pharmaceuticals Ltd and is it undervalued?
Bafna Pharmaceuticals Ltd: the stored intrinsic value estimate is ₹140.98, compared with a stored share price of ₹301.00. The model value is 53.2% below that quote. The model classifies this as overvalued; it is an estimate dependent on the inputs and assumptions, not a price target or a buy/sell recommendation. The estimate uses the available valuation models and weights shown in the Intrinsic Value panel, including earnings, cash-flow and asset-based approaches where data permits. It is not a P/E-only calculation.
What share price and 52-week range are shown for Bafna Pharmaceuticals Ltd?
The stored share price is ₹301.00. Price-data record updated: 14 September 2026, 12:44 pm +05:30. This is not a live quote. The stored 52-week high / low is 318/94.8; this is a rolling range, not a financial-year range.
How have Bafna Pharmaceuticals Ltd's revenue and profit changed?
Revenue for Mar 2025 was ₹146.00 Cr, versus ₹152.00 Cr in Mar 2024 (-3.9% year on year). Net profit for Mar 2025 was ₹4.00 Cr, versus ₹7.00 Cr in Mar 2024 (-42.9% year on year). These are the latest annual periods stored on this page; check the quarterly table separately for more recent developments.
Does Bafna Pharmaceuticals Ltd's profit convert into cash?
For the same Mar 2025 period, operating cash flow was ₹22.00 Cr against net profit of ₹4.00 Cr. Cash flow covered 5.50 times reported profit. Cash generation supports the reported profit for this period; check whether this continues over several years.
What should I check in Bafna Pharmaceuticals Ltd's balance sheet?
Reported borrowings were ₹37.00 Cr in Mar 2026. Read this alongside cash, interest costs and repayment obligations; reserves are an accounting balance and are not the same as available cash.
How should I compare Bafna Pharmaceuticals Ltd's P/E with other stocks?
The stored P/E is 91.50. Compare companies with similar business models, growth, leverage and accounting periods. The industry group on this page is broad, and its average can be affected by outliers. A lower P/E alone does not establish undervaluation.
What could change Bafna Pharmaceuticals Ltd's intrinsic value estimate?
Changes in sustainable earnings, cash generation, capital needs, debt and share count can change the estimate. The displayed model uses a 12% cost of equity and 4% terminal growth assumption where applicable. Higher discount rates or weaker growth generally reduce discounted values. Compare the individual model values and weights, and verify fresh filings before relying on the result.